Journal
AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS
Volume 21, Issue 3, Pages 143-148Publisher
TAYLOR & FRANCIS LTD
DOI: 10.3109/13506129.2014.926267
Keywords
[F-18]Florbetapir; [F-18]flutemetamol; appropriate use criteria; diagnosis; mild cognitive impairment; positron emission tomography
Categories
Funding
- Canadian institutes of Health Research (CIHR) [MOP-11-51-31]
- Alzheimer's Association [NIRG-08-92090]
- Nussia & Andre Aisenstadt Foundation
- Fonds de la recherche en sante du Quebec (Chercheur-boursier)
Ask authors/readers for more resources
Recent advances have made possible the in vivo detection of beta-amyloid (Ab) pathology using positron emission tomography. While the gold standard for amyloid imaging, carbon-11 labeled Pittsburgh compound B is increasingly being replaced by fluorine-18 labeled radiopharmaceuticals, with three already approved for clinical use by US and European regulatory bodies. Appropriate use criteria proposed by an amyloid imaging taskforce convened by the Alzheimer's Association and the Society of Nuclear Medicine and Molecular Imaging recommend restricting use of this technology to the evaluation of patients with mild cognitive impairment or atypical dementia syndromes. While use among asymptomatic individuals is currently viewed as inappropriate due prognostic uncertainty, elevated levels of brain Ab among asymptomatic individuals may represent preclinical Alzheimer's disease. Amyloid imaging is likewise expected to play a role in the design of clinical trials. Though preliminary results suggest amyloid imaging to possess clinical utility and cost-effectiveness, both domains have yet to be assessed systematically. As the field moves toward adoption of a pro-disclosure stance for amyloid imaging findings, it is imperative that a broad range of stakeholders be involved to ensure the appropriateness of emerging policies and protocols.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available